d(GC) - Association of Biotechnology and Pharmacy

More documents

Recommendations

Info

Current Trends in Biotechnology and Pharmacy Vol. 6 (2) 119-144 April 2012, ISSN 0973-8916 (Print), 2230-7303 (Online) of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A, 92: 10560-4. 90. Kimura, A., Nakata, Y., Katoh, O., and Hyodo, H. (1997). c-kit Point mutation in patients with myeloproliferative disorders. Leuk Lymphoma, 25: 281-7. 91. Corless, C.L., Fletcher, J.A., and Heinrich, M.C. (2004). Biology of gastrointestinal stromal tumors. J Clin Oncol, 22: 3813-25. 92. Maleddu, A., Pantaleo, M.A., Nannini, M. and Biasco, G. (2011). The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting. Journal of Translational Medicine, 9: 75-82. 93. Heinrich, M.C., Corless, C.L., Demetri, G.D., Blanke, C.D., von Mehren, M., Joensuu, H., McGreevey, L.S., Chen, C.J., Van den Abbeele, A.D., Druker, B.J., Kiese, B., Eisenberg, B., Roberts, P.J., Singer, S., Fletcher, C.D., Silberman, S., Dimitrijevic, S., and Fletcher, J.A. (2003). Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol, 21: 4342-9. 94. Demetri, G.D., von Mehren, M., Blanke, C.D., Van den Abbeele, A.D., Eisenberg, B., Roberts, P.J., Heinrich, M.C., Tuveson, D.A., Singer, S., Janicek, M., Fletcher, J.A., Silverman, S.G., Silberman, S.L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B.J., Corless, C., Fletcher, C.D., and Joensuu, H. (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 347: 472-80. 95. Verweij, J., Casali, P.G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J.Y., Issels, R., van Oosterom, A., Hogendoorn, P.C., Van Glabbeke, M., Bertulli, R., and Judson, I. (2004). Progression-free survival in Rebecca E. Smith and Juan Miguel Pascale 142 96. gastrointestinal stromal tumours with highdose imatinib: randomised trial. Lancet, 364: 1127-34. Agaram, N.P., Besmer, P., Wong, G.C., Guo, T., Socci, N.D., Maki, R.G., DeSantis, D., Brennan, M.F., Singer, S., DeMatteo, R.P., and Antonescu, C.R. (2007). Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res, 13: 170-181. 97. Heinrich, M.C., Corless, C.L., Blanke, C.D., Demetri, G.D., Joensuu, H., Roberts, P.J., Eisenberg, B.L., von Mehren, M., Fletcher, C.D., Sandau, K., McDougall, K., Ou, W.B., Chen, C.J., and Fletcher, J.A. (2006). Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol, 24: 4764-74. 98. Gounder, M.M. and Maki, R.G. (2011). Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother Pharmacol, 67 Suppl 1: S25- 43. 99. Mendoza, Y., Singh, C., Mewa, J.C., Fonseca, E., Smith, R. and Pascale, J.M. (2011). The beginning of personalized medicine in Panama: molecular and pathological characteristics of Gastrointestinal Stromal Tumors (GIST) from Archival Paraffin-embedded Tissue. Oncology Letters, 2: 941-947. 100. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., Mardis, E., Kupfer, D., Wilson, R., Kris, M., and Varmus, H. (2004). EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A, 101: 13306-11. 101. Derecskei, K., Moldvay, J., Bogos, K., and Timar, J. (2006). Protocol modifications
Current Trends in Biotechnology and Pharmacy Vol. 6 (2) 119-144 April 2012, ISSN 0973-8916 (Print), 2230-7303 (Online) influence the result of EGF receptor immunodetection by EGFR pharmDx(TM) in paraffin-embedded cancer tissues. Pathology Oncology Research, 12: 243- 246. 102. Bhargava, R., Chen, B., Klimstra, D.S., Saltz, L.B., Hedvat, C., Tang, L.H., Gerald, W., Teruya-Feldstein, J., Paty, P.B., Qin, J., and Shia, J. (2006). Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. Cancer, 106: 1857-62. 103. Zinsky, R., Bolukbas, S., Bartsch, H., Schirren, J. and Fisseler-Eckhoff, A. (2010). Analysis of KRAS Mutations of Exon 2 Codons 12 and 13 by SNaPshot Analysis in Comparison to Common DNA Sequencing. Gastroenterol Res Pract, 2010: 789363. 104. Ureshino, N., Sueoka-Aragane, N., Nakamura, T., Sato, A., Komiya, K., Iwanaga, K., Mitsuoka, M., Takeda, Y., Hayashi, S., Sueoka, E. and Kimura, S. (2011). A fully integrated, automated and rapid detection system for KRAS mutations. Oncol Rep, 26: 609-13. 105. Tatsumi, K., Mitani, Y., Watanabe, J., Takakura, H., Hoshi, K., Kawai, Y., Kikuchi, T., Kogo, Y., Oguchi-Katayama, A., Tomaru, Y., Kanamori, H., Baba, M., Ishidao, T., Usui, K., Itoh, M., Cizdziel, P.E., Lezhava, A., Ueda, M., Ichikawa, Y., Endo, I., Togo, S., Shimada, H., and Hayashizaki, Y. (2008). Rapid screening assay for KRAS mutations by the modified smart amplification process. J Mol Diagn, 10: 520- 6. 106. NCBI-GeneTests. MLH1-Related Lynch Syndrome. http://www.ncbi.nlm.nih.gov/ sites/GeneTests/lab/clinical_disease_id/ 316509?db=genetests Accessed 31, Jan 2012 Developing world personalized cancer medicine 143 107. NCBI-GeneTests. MSH2-Related Lynch Syndrome. http://www.ncbi.nlm.nih.gov/ sites/GeneTests/lab/clinical_disease_id/ 316511?db=genetests Accessed 31, Jan 2012 108. NCBI-GeneTests. MSH6-Related Lynch Syndrome. http://www.ncbi.nlm.nih.gov/ sites/GeneTests/lab/clinical_disease_id/ 316513?db=genetests Accessed 31, Jan 2012 109. NCBI-GeneTests. PMS2-Related Lynch Syndrome. http://www.ncbi.nlm.nih.gov/ sites/GeneTests/lab/clinical_disease_id/ 316515?db=genetests Accessed 31, Jan 2012 110. Hampel, H., Frankel, W.L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., Nakagawa, H., Sotamaa, K., Prior, T.W., Westman, J., Panescu, J., Fix, D., Lockman, J., Comeras, I. and de la Chapelle, A. (2005). Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med, 352: 1851-60. 111. Half, E., Bercovich, D. and Rozen, P. (2009). Familial adenomatous polyposis. Orphanet J Rare Dis, 4: 22. 112. Ferla, R., Calo, V., Cascio, S., Rinaldi, G., Badalamenti, G., Carreca, I., Surmacz, E., Colucci, G., Bazan, V. and Russo, A. (2007). Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol, 18 Suppl 6: vi93-8. 113. Gerhardus, A., Schleberger, H., Schlegelberger, B. and Gadzicki, D. (2007). Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: a systematic review. Eur J Hum Genet, 15: 619-27. 114. De Leon Matsuda, M.L., Liede, A., Kwan, E., Mapua, C.A., Cutiongco, E.M., Tan, A., Borg, A. and Narod, S.A. (2002). BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines. Int J
Page 3 and 4: Current Trends in Biotechnology and
Page 29: Current Trends in Biotechnology and
Page 81 and 82:
Current Trends in Biotechnology and
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
6th Annual Convention of Associatio
show all

d(GC) - Association of Biotechnology and Pharmacy

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?